La Radiologia medica · 2026
Safety and efficacy of Glubran-2® endovascular embolization in acute bleeding patients with coagulopathies: a multicenter experience.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giurazza Francesco, Carrubba Claudio, Roccatagliata Pietro, Corvino Fabio, Collettini Federico, Auer Timo Alexander, Chevallier Olivier, Fouad Mohamed, Loffroy Romaric, Niola Raffaella
Аннотация
PURPOSE: This study aims to analyze safety and effectiveness of glue (Glubran-2) embolization in acute bleeding patients with coagulopathies; data were analyzed according to two bleeding risk categories based on coagulation status.
MATERIALS AND METHODS: This retrospective study included patients treated with glue endovascular embolization for acute bleedings in high-volume centers experienced with liquid embolics. Coagulopathy was defined as almost one of the following elements: international normalized ratio (INR) > 1.5; platelet count < 80.000/mm3; and anticoagulant and/or antiplatelet therapies at the time of embolization. If multiple conditions overlapped, patients were classified as high-risk category; otherwise, they were considered as standard risk.
RESULTS: Sixty-seven subjects were considered for this analysis. The underlying causes of bleeding were traumatic in 67.2% and spontaneous in 32.8%. At hospital admission, most patients were hemodynamically stable (86.6%). All patients took anticoagulant or antiplatelet therapies at the time of the intervention; 11.9% presented with INR > 1.5 and 14.9% had platelet counts < 80.000/mm3; 58.2% were classified as standard risk and 41.8% as high risk. Technical success was achieved in all cases while clinical success was obtained in 85%. In-hospital mortality was 6.0%. Procedure-related complications occurred in 4.5%. Comparing patients at high risk with those at standard risk, technical and clinical success rates were similar.
CONCLUSIONS: In this study Glubran-2 appeared to be an effective embolic glue in bleeding patients with coagulopathy, even in those subjects with multiple coagulopathic conditions increasing the risk of bleeding; future studies, including more patients and less trained operators, are required to confirm these outcomes.
MATERIALS AND METHODS: This retrospective study included patients treated with glue endovascular embolization for acute bleedings in high-volume centers experienced with liquid embolics. Coagulopathy was defined as almost one of the following elements: international normalized ratio (INR) > 1.5; platelet count < 80.000/mm3; and anticoagulant and/or antiplatelet therapies at the time of embolization. If multiple conditions overlapped, patients were classified as high-risk category; otherwise, they were considered as standard risk.
RESULTS: Sixty-seven subjects were considered for this analysis. The underlying causes of bleeding were traumatic in 67.2% and spontaneous in 32.8%. At hospital admission, most patients were hemodynamically stable (86.6%). All patients took anticoagulant or antiplatelet therapies at the time of the intervention; 11.9% presented with INR > 1.5 and 14.9% had platelet counts < 80.000/mm3; 58.2% were classified as standard risk and 41.8% as high risk. Technical success was achieved in all cases while clinical success was obtained in 85%. In-hospital mortality was 6.0%. Procedure-related complications occurred in 4.5%. Comparing patients at high risk with those at standard risk, technical and clinical success rates were similar.
CONCLUSIONS: In this study Glubran-2 appeared to be an effective embolic glue in bleeding patients with coagulopathy, even in those subjects with multiple coagulopathic conditions increasing the risk of bleeding; future studies, including more patients and less trained operators, are required to confirm these outcomes.